Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Healthtrust
Julphar
Covington
UBS
Moodys
Cerilliant
US Department of Justice
Colorcon

Generated: August 17, 2018

DrugPatentWatch Database Preview

PHOSLYRA Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Phoslyra, and when can generic versions of Phoslyra launch?

Phoslyra is a drug marketed by Fresenius Medcl and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-three patent family members in seventeen countries.

The generic ingredient in PHOSLYRA is calcium acetate. There are two hundred and seventy-seven drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the calcium acetate profile page.

Drug patent expirations by year for PHOSLYRA
Pharmacology for PHOSLYRA
Synonyms for PHOSLYRA
62-54-4
AC1L1LU9
AC1LANU5
Acetate of lime
acetic acid calcium salt
Acetic acid, calcium salt
Acetic acid, calcium salt (2:1)
AI3-02903
AKOS015904560
AN-23726
API0024654
Brown acetate
Brown Acetate of Lime
Ca(OAc)2
Calac
Calcium acetate
Calcium Acetate (Fragrance Grade)
Calcium acetate (USP)
Calcium acetate [USAN:JAN]
Calcium acetate [USP:JAN]
Calcium Acetate 23% 10M
Calcium acetate hydrate, Puratronic
calcium acetate salt
Calcium Acetate, FCC
CALCIUM ACETATEULTRA PURE
Calcium di(acetate)
Calcium diacetate
calcium diacetate, CAc - acetic acid, calcium salt
calcium ethanoate
calcium(2+) bis(acetate ion)
calcium(II) acetate
CCRIS 4921
CHEBI:3310
CHEMBL1200800
D00931
D0F1GS
DB00258
DTXSID0020234
E263
EC 200-540-9
EINECS 200-540-9
Eliphos
FEMA No. 2228
FT-0623376
GE2473
Gray acetate
Gray Acetate of Lime
Grey acetate
HSDB 928
I14-16503
IN017428
J-519530
Lime acetate
Lime pyrolignite
LS-2337
Niacet calcium acetate tech
OR033975
OR205936
PhosLo
Phoslo (TN)
Phoslo Gelcaps
Procalamine
Pyrolignite of lime
RP22176
Sanopan
SC-18378
SCHEMBL23872
Sorbo-calcian
Sorbo-calcion
Teltozan
UNII-Y882YXF34X
Vinegar salts
VSGNNIFQASZAOI-UHFFFAOYSA-L
Y882YXF34X

US Patents and Regulatory Information for PHOSLYRA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Medcl PHOSLYRA calcium acetate SOLUTION;ORAL 022581-001 Apr 18, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Fresenius Medcl PHOSLYRA calcium acetate SOLUTION;ORAL 022581-001 Apr 18, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Fresenius Medcl PHOSLYRA calcium acetate SOLUTION;ORAL 022581-001 Apr 18, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for PHOSLYRA
Drugname Dosage Strength RLD Date
➤ Subscribe Oral Solution 667 mg/5 mL ➤ Subscribe ➤ Try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for PHOSLYRA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2018 00006 Denmark ➤ Try a Free Trial PRODUCT NAME: PATIROMER SORBITEX CALCIUM AND ANY SALTS AND DERIVATIVES THEREOF; REG. NO/DATE: EU/1/17/1179/001-009 20170721
C/GB03/033 United Kingdom ➤ Try a Free Trial PRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321
/1997 Austria ➤ Try a Free Trial PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
2008006 Lithuania ➤ Try a Free Trial PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Cantor Fitzgerald
Harvard Business School
Deloitte
UBS
QuintilesIMS
Johnson and Johnson
Moodys
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.